Study of SC-102 in Patients With Advanced Solid Tumors
ConditionAdvanced Solid Cancers
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-75
SponsorTianjin ConjuStar Biologics Co., Ltd.
About this trial
This study will evaluate the safety, PK profile, and anti-cancer efficacy of SC-102 in subjects with advanced solid tumors
Eligibility criteria
Qualifiers
Subjects voluntarily agree to participate in the study and sign the Informed Consent Form (ICF).
Aged 18 to 75 years at the time of signature of the ICF, without gender limitation.
Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.
Life expectancy of ≥ 3 months as assessed by the investigator.
Disqualifiers
History of other malignancy(ies) within 3 years before signing the ICF, except for cured basal cell carcinoma or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, papillary carcinoma of the thyroid gland, carcinoma in situ of the duct in situ, or other malignant tumors that have survived without disease for more than 5 years.
Any anticancer treatment, including experimental treatments, within 4 weeks before the first dose of the study drug.
Radiotherapy to >30% of the bone marrow or extensive radiotherapy within 4 weeks, or local radiotherapy (e.g., radiation therapy to the thoracic spine and ribs) within 7 days, prior to the first dose of the study drug.
Uncontrolled central nervous system metastases.
Trial design
Treatments tested in this trial
- SC-102
Treatment groups
120 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov